A patient with uncontrolled postherpetic neuralgia pain has been taking paracetamol 1 g four times daily. Which medication is most appropriate as first-line therapy for neuropathic pain?

A patient with uncontrolled postherpetic neuralgia pain has been taking paracetamol 1 g four times daily. Which medication is most appropriate as first-line therapy for neuropathic pain?

• A. Gabapentin
• B. Amitriptyline
• C. Paracetamol
• D. Morphine

Answer: (A)

Neuropathic pain, like postherpetic neuralgia, responds best to medications that dampen abnormal nerve signaling. Gabapentin fits this role well because it binds to the alpha-2-delta subunit of voltage-gated calcium channels in the spinal cord and brain, reducing the release of excitatory neurotransmitters that drive pain signals. This mechanism directly addresses the nerve hyperexcitability seen in neuropathic pain, making it effective where simple analgesics such as paracetamol fall short. Gabapentin also tends to have a more favorable safety profile compared with amitriptyline (which can cause dizziness, sedation, and anticholinergic effects, especially in older patients) or morphine (which carries higher risks of dependence and limited efficacy for neuropathic pain). Starting with gabapentin allows gradual dose titration to achieve pain relief while monitoring for side effects like dizziness or somnolence and adjusting for kidney function as needed. In short, addressing the neuropathic component directly with a gabapentinoid offers the best chance to improve uncontrolled PHN pain when paracetamol alone is insufficient.

Neuropathic pain, like postherpetic neuralgia, responds best to medications that dampen abnormal nerve signaling. Gabapentin fits this role well because it binds to the alpha-2-delta subunit of voltage-gated calcium channels in the spinal cord and brain, reducing the release of excitatory neurotransmitters that drive pain signals. This mechanism directly addresses the nerve hyperexcitability seen in neuropathic pain, making it effective where simple analgesics such as paracetamol fall short. Gabapentin also tends to have a more favorable safety profile compared with amitriptyline (which can cause dizziness, sedation, and anticholinergic effects, especially in older patients) or morphine (which carries higher risks of dependence and limited efficacy for neuropathic pain). Starting with gabapentin allows gradual dose titration to achieve pain relief while monitoring for side effects like dizziness or somnolence and adjusting for kidney function as needed. In short, addressing the neuropathic component directly with a gabapentinoid offers the best chance to improve uncontrolled PHN pain when paracetamol alone is insufficient.